60 Degrees Pharmaceuticals, Inc. (SXTP)

The company's stock price experienced a significant decline of 90.24% between January 10, 2025, and January 8, 2026. In July 2025, the company intended to seek a Minor Use Minor Species (MUMS) designation from the FDA for acute canine babesiosis and determined the total addressable market (TAM) for human babesiosis treatment to be up to $1.1 billion through patent expiration in 2035. In September 2025, management presented at an H.C. Wainwright conference. In October 2025, the first patient in its relapsing babesiosis study tested negative for infection, and a Breakthrough Therapy Designation request was submitted to the FDA. In November 2025, the company reported its Third Quarter 2025 financial results, with net product revenue increasing 223% year-over-year to $438 thousand, and Arakoda pharmacy deliveries increasing by 14%, but a gross loss of approximately $100 thousand was reported. In December 2025, 60 Degrees Pharmaceuticals announced the planned expansion of Arakoda sales and marketing initiatives in 2026 and the initiation of additional clinical sites for babesiosis treatment trials. In January 2026, the stock price increased by 4.06% on January 8, 2026, and by 2.71% on January 9, 2026, and an investor webinar provided updates on commercial progress, clinical pipeline, and regulatory strategy.

Demand for 60 Degrees Pharmaceuticals' products, particularly Arakoda, is influenced by travel patterns, with the pandemic initially reducing demand. However, there is increasing market demand for Arakoda among prescribers and off-label demand for chronic and relapsing babesiosis. The company is expanding its sales and marketing initiatives for Arakoda in 2026 to capitalize on this growing demand. A supply chain disruption in early 2025 temporarily impacted sales, but this issue has largely been resolved.

60 Degrees Pharmaceuticals, Inc. (SXTP) is a specialty pharmaceutical company focused on developing and commercializing therapies for infectious diseases, operating in the Biotechnology and Pharmaceutical industry. Its major products include Arakoda (tafenoquine), an FDA-approved antimalarial, Tafenoquine (Arakoda regimen) in Phase II clinical trials for COVID-19, babesiosis, fungal pneumonias, and candidiasis, and Celgosivir, under development for Zika, respiratory viruses, and dengue.

60 Degrees Pharmaceuticals, Inc. is headquartered in Washington, D.C., and Arakoda is commercially available in the U.S. and Australia. The company has a subsidiary in Australia and collaborates with research organizations in the U.S., Australia, and Singapore. It also has international offices or distributors in Sweden and Australia.

60 Degrees Pharmaceuticals has focused on scientific and operational advancements in malaria prevention and tick-borne illness therapies, with a news sentiment score of 0.45. Analyst ratings are generally positive, with a consensus rating of "Strong Buy" or "Hold". Positive developments include a successful commercial pilot for Arakoda, expansion plans for Arakoda sales and marketing, positive data from a babesiosis study, and insider buying by the CEO. Mixed signals include the FDA declining the Breakthrough Therapy Designation request for babesiosis, a one-time inventory write-off in Q3 2025, a temporary supply chain disruption, and a significant decline in stock price.

The ownership structure includes institutional investors (0.60% to 1.04%), insiders (2.51% to 33.34%), and retail investors (around 96.61%). Major institutional owners include DRW Securities, LLC, Geode Capital Management, Llc, and Fidelity Extended Market Index Fund (FSMAX). The largest individual owner is Geoffrey S. Dow, the CEO and Chairman, who has recently engaged in insider buying.